NCT06990711View on ClinicalTrials.gov

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

June 30, 2028

Conditions
Antibody Mediated Rejection of Lung Transplant
Interventions
DRUG

Siltuximab

Interleukin-6 blockade

DRUG

Placebo

Siltuximab placebo IV

Trial Locations (2)

63110

Washington University School, of Medicine, Barnes-Jewish Hospital, St Louis

84112

University of Utah, Saint Lake City

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

University of Utah

OTHER

lead

Washington University School of Medicine

OTHER